Skip to Main Content
Contribute Try STAT+ Today

Paul Knoepfler, a stem cell researcher at the University of California, Davis and author of The Niche blog, has warned for years about the proliferation of unlicensed stem cell clinics and the danger they pose to both patients and legitimate stem cell research. He was pleased this week to see the FDA announce a crackdown — and then back up that rhetoric with action. The FDA sent a stern warning letter to a Florida clinic that left three women legally blind after an unapproved treatment. And federal marshals raided a California clinic and seized dangerous therapies, made in part from smallpox vaccine.

But while he welcomed the actions, Knoepfler cautioned that it’s still unclear how aggressively the FDA will move against the hundreds of unlicensed clinics peddling dubious remedies. STAT spoke to him about what it would take to truly clean up the industry. The conversation has been lightly edited for clarity.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.